Mary Caffrey

The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.

Liraglutide, a GLP-1 receptor agonist sold as Victoza, becomes the second diabetes therapy to receive the cardiovascular indication.

The Duke Center for Health Data Science was in the planning stages before Robert Califf, MD, departed for a stint as FDA commissioner.

The new law includes requirements that drugmakers reveal discounts for pharmacy benefit managers and prevents gag rules on pharmacists who want to suggest cheaper alternatives.

Experts hoped that Medicaid expansion would direct the previously uninsured into primary care and reduce reliance on the emergency department. What happened is more complicated.

Staff at mental health hospitals have long believed that tobacco helped calm patients, when in fact the nicotine only covered symptoms of withdrawal.

Cardiovascular outcomes trials and a photography ban that dominated social media were big news at the 77th Scientific Sessions of the American Diabetes Association.

The researchers' approach to finding the compound could be used to find cures in other diseases.

State-level decisions on whether to expand Medicaid had ripple effects across the rest of the healthcare insurance market, according to a report by the Office of the CMS Actuary in Health Affairs.

The collaboration between a digital behavioral health provider and an insurer comes as CMS admits challenges setting up the Medicare Diabetes Prevention Program.

Studies presented at the 77th Scientific Sessions of the American Diabetes Association show that the combination therapy helps patients with the highest glycated hemoglobin levels gain control quickly.

The study's lead author said that complications from cardiovascular disease remain an unmet clinical challenge in type 2 diabetes.

A light-hearted format for the discussion at the 77th Scientific Sessions of the American Diabetes Association still brought out the seriousness of the issue: too many with type 2 diabetes have poor glycemic control, and another medication may not be the answer.

The long-awaited results from CANVAS show a reduced risk of cardiovascular events. The study's lead author said clinicians should balance the significant benefits of the drug against the potential harms for a small number of patients with known risks.

Results presented at the 77th Scientific Sessions of the American Diabetes Association are for combinations with ertugliflozin, an investigational SGLT2 inhibitor before FDA.

At a symposium at the 77th Scientific Sessions of the American Diabetes Association, experts suggested that the relationship between heart failure and diabetes is finally getting the attention it deserves.

The studies are the first to focus on use of PCSK9 inhibitors in patients with diabetes. Alirocumab, sold as Praluent, is expected to report its cardiovascular outcomes trial in early 2018.

No one questions the long-term savings that the Diabetes Prevention Program will bring to Medicare, but getting it off the ground will require several steps that have never been done before, including a new payment model.

With the nation's largest commercial payer on board, the maker of the at-home DNA colon cancer screening test will put more focus on physician education and consumer awareness, with the hope of increasing screening rates for a test that patients find uncomfortable and inconvenient.

The investigational oral therapy, upadacitinib, is a potential competitor for Pfizer's JAK inhibitor, which treats patients who are not responding adequately to DMARDs.

Being isolated due to being overweight can have long-term health consequences, and the study's lead author said reducing stigma should be part of anti-bullying efforts.

While alcohol is known to limit skeletal muscle growth, few studies have looked at the relationship between sarcopenia and problem drinking.

The enzyme that affects the body's ability to process LDL cholesterol was found to be correlated with A1C levels. A symposium on the topic will be part of this weekend's 77th Scientific Sessions of the American Diabetes Association.

CMS is giving seniors until September 30, 2017, to request a waiver from all or part of the penalties they face for not enrolling on time for Medicare.

The study said the alternative to BMI offers a better way to measure visceral fat, which poses a greater cardiovascular threat.

The change reflects scientific advances that have converted AIDS from a certain death sentence to a condition that can be managed with proper diagnosis and treatment.

The #Coverage2Control campaign begins a year after the announcement that UnitedHealth would shift most adult type 1 diabetes patients toward Medtronic technology, or require them to pay significant out-of-pocket costs. More significantly, JDRF reports payers are saying they will not fund the artificial pancreas.

US Senator Chuck Grassley (R-Iowa) asked why Medicaid did not move earlier to force Mylan to pay what it owed in rebates for the epinephrine injector.

Researchers from the United Kingdom combed studies to figure out which of several indicators, such as body mass index or waist circumference, were predictors of future cardiac events or health conditions, like hypertension or prediabetes.

While regulators long ago saw enough cardiovascular safety data to approve insulin degludec, full trial results will be presented June 12 at the American Diabetes Association Scientific Sessions in San Diego.